UK markets close in 1 hour 9 minutes

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.2200+0.0099 (+0.31%)
As of 10:06AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.2101
Open3.1650
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's range3.1650 - 3.4610
52-week range0.3900 - 5.0000
Volume74,582
Avg. volume234,343
Market cap117.466M
Beta (5Y monthly)2.08
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    CytRx to Present at Upcoming Investor Conferences

    CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to present in the following upcoming conferences:

  • Business Wire

    CytRx Comments on Quarterly Results and Year-to-Date Progress

    CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the first quarter ended March 31, 2021. In addition, CytRx highlighted developments pertaining to its agreements with Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") and ImmunityBio, Inc. (NASDAQ:IBRX) ("ImmunityBio") as well as Centurion Biopharma. The Company’s 10-Q was filed on May 13, 2021.

  • Business Wire

    CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

    CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that the ORARIALS-01 pivotal trial for arimoclomol in Amyotrophic Lateral Sclerosis ("ALS") did not meet primary and secondary endpoints to show benefit in people living with the disease. According to Orphazyme, no important safety signals were reported in the trial. Topline data will be presented at the upcoming virtual European Network to Cure ALS meeting and complete data from the study will be published later this year.